Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer

  title={Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer},
  author={Edward T. Morgan and Kerry B. Goralski and Micheline Piquette-Miller and Kenneth W. Renton and Graham R. Robertson and Madhusudana Rao Chaluvadi and Kellie A. Charles and Stephen John Clarke and Marina Kacevska and Christopher Liddle and Terrilyn A. Richardson and Rohini Sharma and Christopher J. Sinal},
  journal={Drug Metabolism and Disposition},
  pages={205 - 216}
This article is a report on a symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics and held at the Experimental Biology 07 meeting in Washington, DC. The presentations discussed the phenomenology, clinical consequences, and underlying mechanisms of cytochrome P450 and drug transporter regulation by inflammatory and infectious stimuli. Although considerable insights into the links between inflammatory mediators and altered hepatic drug clearance pathways… 

Figures and Tables from this paper

Regulation of Drug Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer

Under conditions of innate immune system activation, the functions of specific cytochrome P450 enzymes, other drug metabolizing enzymes, and drug transporters are altered in the liver, small intestine, lung, kidney, and central nervous system, leading to corresponding changes in protein levels and function.

Drug-Cytokine Interactions

A historical overview of drug-cytokine ­interactions is provided, recent advances are discussed and clinical scenarios in which infections or inflammation might lead to abnormal drug handling and drug responses are examined.

Drug disposition in pathophysiological conditions.

Altered regulation of DMEs and transporters in a multitude of disease states will contribute towards future development of powerful in vitro and in vivo tools in predicting the drug response and opt for better drug design and development.

Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents

What is known about inflammation, cancer, and CYP‐mediated drug metabolism is focused on; clinical and pharmacologic data regarding novel immunomodulators are discussed; and their potential interactions with concurrent agents are considered.


Some of the main experimental and clinical data of altered drug metabolizing enzyme system in the case of changes in the immune system due to inflammation or vaccination are summarized.

Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response

The current state of knowledge on drug transporter expression during acute and chronic inflammatory conditions is discussed and how the altered expression of these transporters may modify the pharmacokinetics and pharmacodynamics of clinically important therapeutics is postulated.

“Target-Site” Drug Metabolism and Transport

Taken together, the research summarized herein can provide for an increased understanding of potential barriers to drug efficacy and allow for a more rational approach for developing safe and effective therapeutics.

Clinical and Molecular Perspectives on Inflammation‐Mediated Regulation of Drug Metabolism and Transport

Clinical and in vitro evidence finds inflammation and pro‐inflammatory cytokines to be important factors in regulation of drug‐metabolizing enzymes and transporters and to further support personalized medicine.

Inflammation and pharmacokinetics: potential implications for HIV-infection

Preclinical and clinical studies show that inflammation leads to a downregulation of certain drug metabolizing enzymes and both up and down regulation of transporters depending on the transporter and cell type, leading to potential absorption, distribution, and clearance changes.

Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

  • E. Morgan
  • Biology, Medicine
    Clinical pharmacology and therapeutics
  • 2009
The genesis of inflammatory reactions is reviewed, and the relevance of the inflammation‐related regulation of cytochrome P450 enzymes to clinical drug–disease and drug–drug interactions is discussed.



Regulation of drug metabolism and disposition during inflammation and infection

  • K. Renton
  • Biology, Medicine
    Expert opinion on drug metabolism & toxicology
  • 2005
For any drug that is metabolised by CYP and has a narrow therapeutic index, there is a significant risk in placing patients in a position where an infection or inflammatory response might lead to aberrant drug handling and an adverse drug response.

Cytochrome P450 regulation and drug biotransformation during inflammation and infection.

In clinical medicine there are numerous examples of a decreased capacity to handle drugs during infections and disease states that involve an inflammatory component, which often results in altered drug responses and increased toxicities.

Regulation of drug-metabolizing enzymes and transporters in inflammation.

Regulation of hepatic flavin monooxygenases, UDP-glucuronosyltransferases, sulfotransferases, glutathione S-transferases and hepatic transporters during the inflammatory response, exhibits similarities and differences with regulation of CYPs.

Alteration of drug biotransformation and elimination during infection and inflammation.

  • K. Renton
  • Biology
    Pharmacology & therapeutics
  • 2001

Regulation of cytochromes P450 during inflammation and infection.

In contrast to the down-regulation of P450s in the liver, the induction of several forms in this and other tissues suggests a more specific homeostatic role of these effects, e.g., in generation or catabolism of bioactive metabolites.

The regulation of cytochrome P450 2E1 during LPS-induced inflammation in the rat.

Decreased Expression and Activity of P-GIycoprotein in Rat Liver During Acute Inflammation

This is the first evidence that expression of P-gp is modulated in response to experimentally-induced inflammation, and it is hoped that this will help clarify the role of inflammation in the development of multidrug resistance.

Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice.


It is suggested that endotoxin-induced inflammation in mice causes differential regulation of PGP in liver and kidney, thereby altering the clearance profile of DOX.